“Off-label prescribing” means that a medicine is being used in a way
that is different to that described in the license for it, for
example, using a medicine for a different illness to that stated in
the license.1 Novo Nordisk acknowledges that all licensed
prescribers have the choice to prescribe treatments outside of their
intended purpose, or approved parameters of use, Novo Nordisk does not
endorse this in any way. Novo Nordisk recommends all prescriptions are
in line with a medicines approved Summary of Product Characteristics (SmPC).
We’ve been closely monitoring how our medicines are being portrayed
in both mainstream and social media, and we share ongoing concerns
that off-label promotion and use of our medicines is putting supply at
risk for people living with diabetes in the UK.
Prescription only medicines should be used in line with their
approved indication. Any decisions made regarding treatment options
should always be made in consultation with a healthcare professional
and require strict medical supervision.
While we are subject to strict regulations regarding promotion of
our medicines — which includes how we talk about them publicly — we
are continuing to take steps to ensure accurate information is
available to support the responsible use of our medicines. This includes:
- All healthcare professional (HCP) and educational materials
for our medicines focus on the Medicines and Healthcare products
Regulatory Agency (MHRA) approved indications only, in compliance
with all applicable regulations.
- We do not encourage
off-label use of our medicines and actively discourage off-label
prescriptions and promotion from HCPs and retailers.
offer a comprehensive programme of clinical training to any HCP who
utilises our medications as part of their clinical practice. This
includes information around the specific indication, suitable
patient population, dosing, administration, and follow-up.
- In response to our current supply and demand situation, we are
working closely with the Department of Health and Social Care on how
HCPs should prescribe our medicines in line with local laws and
- Collaborating with regulators and health
authorities to take action against activity that violates relevant
regulations and codes, such as promoting our medicines to the
- We work to ensure reporters and external stakeholders
have accurate information about our medicines and take reasonable
measures to inform the press of misinformation and issue
- Where Novo Nordisk is made aware of an illicit
online offering for its medicines (e.g. selling without requiring
prescription, counterfeit, or promoting off-label use to the public)
on websites, marketplaces or social media, Novo Nordisk
systematically assesses the best course of action, which can include
attempting to remove these from the internet or further